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Abstract
IDH mutations are found in the majority of adult, diffuse, low-grade and anaplastic gliomas and are also frequently
found in cartilaginous tumors. Ollier disease and Maffucci syndrome are two enchondromatosis syndromes
characterized by the development of multiple benign cartilaginous tumors due to post-zygotic acquisition of IDH
mutations. In addition to skeletal tumors, enchondromatosis patients sometimes develop gliomas. The aim of the
present study was to determine whether gliomas in enchondromatosis patients might also result from somatic IDH
mosaicism and whether their characteristics are similar to those of sporadic IDH-mutated gliomas. For this purpose, we
analyzed the characteristics of 6 newly diagnosed and 32 previously reported cases of enchondromatosis patients who
developed gliomas and compared them to those of a consecutive series of 159 patients with sporadic IDH-mutated
gliomas. As was the case with sporadic IDH mutated gliomas, enchondromatosis gliomas were frequently located in
the frontal lobe (54 %) and consisted of diffuse low-grade (73 %) or anaplastic gliomas (21 %). However, they were
diagnosed at an earlier age (25.6 years versus 44 years, p < 0.001) and were more frequently multicentric (32 % versus
1 %, p < 0.001) and more frequently located within the brainstem than sporadic IDH mutated gliomas (21 % versus 1 %,
p < 0.001). Their molecular profile was characterized by IDH mutations and loss of ATRX expression. In two patients, the
same IDH mutation was demonstrated in the glioma and in a cartilaginous tumor. In contrast to sporadic IDH mutated
gliomas, no enchondromatosis glioma harbored a 1p/19q co-deletion (0/6 versus 59/123, p = 0.03). The characteristics
of gliomas in patients with enchondromatosis suggest that these tumors, as cartilaginous tumors, result from somatic
IDH mosaicism and that the timing of IDH mutation acquisition might affect the location and molecular characteristics
of gliomas. Early acquisition of IDH mutations could shift gliomagenesis towards the brainstem thereby mimicking the
regional preference of histone mutated gliomas.
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Introduction
Mutations in the IDH1 or IDH2 genes are found in the
majority of adult diffuse grade II and grade III gliomas
and are considered as the earliest oncogenic event in these
tumors [50]. These mutations result in the abnormal pro-
duction of 2-hydroxyglutarate (2-HG) which is structurally
similar to alpha-ketoglutarate. 2-HG competitively inhibits
multiple alpha-ketoglutarate enzymes leading to histone
and DNA hypermethylation, altered cell differentiation,
activation of enzymes implicated in HIF degradation and
PDGFRA overexpression [14, 26, 30, 47]. In addition to
gliomas, IDH mutations are particularly frequent in cartil-
aginous tumors [2, 50]. Ollier disease and Maffucci syn-
drome are two rare non-hereditary enchondromatosis
syndromes characterized by the development of multiple
benign cartilaginous tumors (enchondromas). Enchondro-
mas appear during childhood and may progress to chon-
drosarcomas in up to 30 % of cases [3, 36]. In Maffucci
syndrome, enchondromas are associated with soft tissue
hemangiomas. The analysis of IDH mutations in multiple
cartilaginous tumors and non-neoplastic tissues from
enchondromatosis patients led to the conclusion that
these pathologies are due to early post-zygotic acquisition
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of IDH mutations, resulting in somatic mosaic mutations
of IDH1 or IDH2 [3, 36]. In addition to skeletal tumors,
enchondromatosis patients may develop other neoplasm
including juvenile granulosa tumors, cholangiocarcino-
mas, pituitary adenomas, acute myeloid leukemia and
gliomas. The aim of the present study was to determine
whether gliomas in enchondromatosis patients might also
result from somatic IDH mosaicism and whether their
characteristics are similar to those of sporadic IDH-mu-
tated gliomas. For this purpose, we analyzed the character-
istics of 6 newly diagnosed and 32 previously reported
cases of enchondromatosis patients who developed
gliomas, and compared them to those of a consecutive
series of 159 patients with sporadic IDH-mutated gliomas.
Materials and methods
We retrospectively reviewed the medical and radiological
records of 6 patients with Ollier disease (n = 5) or
Maffucci syndrome (n = 1) who were referred to our
neuro-oncology departments (Pitié-Salpêtière Hospital
in Paris, Hospices Civils of Lyon, CHU of Bordeaux and
Rennes) for the diagnosis of glioma, as well as 159 con-
secutive patients who were diagnosed with an IDH1 or
IDH2 mutated sporadic glioma between 2010 and 2014
(Hospices Civils of Lyon). Multicentric gliomas were de-
fined as multiple gliomas without connecting T2/FLAIR
signal abnormality and distinguished from multifocal gli-
omas (i.e. multiple gliomas with connecting T2/FLAIR
signal abnormality) [1]. IDH mutations and 1p/19q co-
deletion status were determined based on DNA ex-
tracted from blood and FFPE tumor using a standard
protocol (Qiagen, QIAmp DNA mini Kit). IDH1 codon
132 and IDH2 codon 172 were sequenced using the
Sanger method with the following primers: IDH1-
Forward: TGTGTTGAGATGGACGCCTATTTG; IDH1-
Reverse: TGCCACCAACGACCAAGTC; IDH2-Forward:
GCCCGGTCTGCCACAAAGTC and IDH2-Reverse: TT
GGCAGACTCCAGAGCCCA, as previously reported
[21]. The 1p/19q co-deletion was determined based on
the loss of heterozygosity technique (LOH) using micro-
satellite polymorphism markers as previously described
[18]. In 3 patients, 1.5 μg of DNA extracted from frozen
tumor tissue was outsourced to Integragen Company for
the determination of the genomic profile based on Illu-
mina SNP arrays [22]. In enchondromatosis gliomas, im-
munohistochemistry was performed on 4 μm thick
sections of formalin-fixed paraffin embedded blocks with
a Ventana Benchmark XT Device. The following anti-
bodies were used after antigen retrieval to assess the
expression of ATRX (anti-ATRX, Sigma, polyclonal, dilu-
tion 1/400), IDH1R132H (anti-IDH1R132H, Dianova,
clone H09, dilution 1/50) and TP53 (clone DO.7, Dako,
dilution 1/200). Previously reported cases of patients with
Ollier disease or Maffucci syndrome who developed
gliomas were identified through PubMed searches from
January 1970 until September 2015 using the terms “Ollier
disease”, “Maffucci syndrome”, “glioma” and “brain
tumor”. We retrieved all relevant articles and checked
additional references quoted in these articles. Categorical
comparisons were performed using Fisher’s exact test and
a t-test was used for quantitative variables. The threshold
for statistical significance was p = 0.05.
Results
The characteristics of our 6 patients are presented in
Table 1 and those of the 32 previously published patients
are shown in Additional file 1: Table S1 [5–8, 11, 12, 15,
16, 19, 20, 23–25, 31–35, 37–40, 43–46, 48, 49]. The char-
acteristics of all of the patients are summarized in Table 2.
The diagnosis of Ollier disease (n = 28) or Maffucci
syndrome (n = 10) was made during childhood based on
the occurrence of multiple enchondromas predominat-
ing on the articulations of the knees, hands and toes.
The median age at glioma diagnosis was 25.6 years. At
this time, six patients (19 %) had a previous history of
chondrosarcoma. Clinical presentation consisted of a
variable association of seizures (38 %), progressive focal
deficits (41 %) and intracranial hypertension (21 %).
Radiological presentation was suggestive of diffuse gli-
oma in all of the patients (Fig. 1). Tumors were most
frequently located in the frontal lobe (54 %) and in the
brainstem (21 %). Contrast enhancement was present in
27 % of cases. Twelve patients (32 %) had multicentric
gliomas that were synchronous in eleven patients and
metachronous in one patient. Multicentric gliomas were
confined to the hemispheres in 8 patients and involved
both the hemispheres and the brainstem in 4 patients.
Two patients had gliomatosis cerebri. Ten patients
(36 %) had another intracranial tumor at the time of gli-
oma diagnosis (skull base enchondroma n = 7, pituitary
adenoma n = 2, skull base chondrosarcoma n = 1).
The glioma was histologically proven in 33 patients.
Among the 5 patients without histological diagnosis, 4
patients had a typical aspect of brainstem glioma con-
sisting of an infiltrative intra-axial T2/FLAIR hypersignal
without contrast-enhancement, and 1 patient had an as-
pect suggestive of hemispheric low-grade glioma that
was managed with initial follow-up (patient 2, Fig. 1).
Histology consisted of diffuse low-grade glioma in 24 pa-
tients (73 %), anaplastic glioma in 7 patients (21 %) and
glioblastoma in 2 patients (6 %). An astrocytic (n = 22,
66 %) or oligo-astrocytic phenotype (n = 8, 25 %) was
more frequently observed than a pure oligodendroglial
phenotype (n = 3, 9 %). IDH mutations were assessed in
8 cases (based on sequencing in 6 patients and on im-
munohistochemistry only in 2 patients) and detected in
the tumors of 7 patients (IDH1 R132H n = 5, IDH2
R172S n = 2). In the negative case, no expression of
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IDH1 R132H was detected on immunohistochemistry,
but other IDH mutations were not assessed [38]. In two
patients (patient 5 and a previously reported patient
[34]) the presence of an IDH mutation could be analyzed
in both the glioma and a skeletal tumor and the same
mutation (IDH1 R132H in patient 5 and IDH2 R172S in
[34]) was identified in these tumors. Since none of our
patients underwent a biopsy of more than one glioma,
the analysis of IDH mutations in different gliomas from
the same patient could not be performed. No 1p/19q co-
deletion was identified in the 6 cases in which it was
assessed (oligo-astrocytoma n = 4, oligodendroglioma
n = 1, glioblastoma n = 1). TP53 expression was stud-
ied in 6 patients and found to be expressed in 5
Table 1 Clinical, histological and molecular characteristics of our 6 patients with enchondromatosis who developed glioma
Age at glioma
diagnosis (years)
Sex Histology IDH mutation 1p19q
co-deletion
ATRX loss of
expression
Location Multi-centric History of
chondrosarcoma
Survival (years)
Ollier disease
1 28 F OAII IDH1 R132H No Yes T (n = 1),Fr (n = 1) Yes No 2.5+
2 26 M - - - - Fr (n = 2) Yes Yes 1+
3 30 F OII IDH1 R132H No Yes Fr (n = 1),T (n = 1) Yes No 4
4 31 M GBM IDH1 R132H No Yes Fr (n = 2),P (n = 1) Yes No 0.75
5 31 F OAIII IDH1 R132H No Yes Fr No Yes 1.5+
Maffucci syndrome
6 30 M OAII IDH2 R132S No Yes B No No 3+
M male, F female, OAII/III grade II/III oligo-astrocytoma, OII grade II oligodendroglioma, GBM glioblastoma, −: data not available, T temporal, P parietal, Fr frontal, B
brainstem, +: alive at last news
Table 2 Summary of the clinical, histological and molecular characteristics of Ollier disease (OD), Maffucci syndrome (MS),
enchondromatosis (OD +MS) -present series and literature- and sporadic IDH mutated glioma patients
Ollier disease Maffucci syndrome Enchondro-matosis Sporadic IDH mutated
gliomas
Enchondro-matosis versus sporadic
IDH mutated glioma P-value
N 28 10 38 159
N of gliomas 45 12 57 161
Sex ratio (M/F) 18/10 7/3 25/13 91/68 0.4
Median age (years, range) 24.7 (6–46) 28.1 (17–39) 25.6 (6–46) 44 (6–81) <0.0001
Histology
Grade II 68 % (17/25) 87.5 % (7/8) 72.7 % (24/33) 47 % (75/159) 0.01
Grade III 24 % (6/25) 12.5 % (1/8) 21.2 % (7/33) 39 % (62/159) 0.05
Grade IV 8 % (2/25) 6.1 % (2/33) 14 % (22/159) 0.4
Location
Frontal 53.4 % (24/45) 58 % (7/12) 54.1 % (31/57) 67,1 % (108/161) 0.1
Parietal 4.4 % (2/45) 3.6 % (2/57) 7.5 % (12/161) 0.4
Insular 4.4 % (2/45) 3.6 % (2/57) 5,6 % (9/161) 0.7
Temporal 13.3 % (6/45) 10.5 % (6/57) 11.8 % (19/161) 1
Occipital 2.2 % (1/45) 1.8 % (1/57) 1.9 % (3/161) 1
Brainstem 15.7 % (7/45) 42 % (5/12) 21 % (12/57) 0.6 % (1/161) <0.0001
Gliomatosis 4.4 % (2/45) 3.6 % (2/57) 5 % (8/161) 1
Thalamic 2.2 % (1/45) 1.8 % (1/57) 0.6 % (1/161) 1
Multicentric 39.2 % (11/28) 10 % (1/10) 31.6 % (12/38) 1.3 % (2/159) <0.0001
IDH mutation 83 % (5/6) 100 % (2/2) 87.5 % (7/8) 100 % -
1p/19q co-deletion 0 % (0/5) 0 % (0/1) 0 % (0/6) 48 % (59/123) 0.03
Other intracranial Tumor 25 % (7/21) 43 % (3/7) 36 % (10/28) 1.9 % (3/159) <0.0001
History of chondrosarcoma 12.5 % (3/24) 42.8 % (3/7) 19.3 % (6/31) 0 % <0.0001
M male, F female
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patients. In an additional patient, sequencing demon-
strated missenses TP53 mutations [34]. ATRX expres-
sion was studied in 5 patients. A homogeneous loss
of expression was observed in 4 patients and a het-
erogeneous loss of expression in 1 patient (patient 3).
Genomic profiles of the tumors were obtained for 2
patients; one patient had an isolated LOH of the 17p
region covering the TP53 locus (patient 3), and the
other patient had a LOH of chromosome 9 associated
with partial losses of chromosomes 14q and 15q and
a partial gain of chromosome 11q (patient 5). In pa-
tient 3, double staining with anti-ATRX and anti-
IDH1 R132H antibodies identified: (i) areas with
maintained ATRX expression in tumor cells, and (ii)
areas with diffuse loss of ATRX expression in tumors
cells. In these last areas, some very rare IDH1 R132H
Fig. 1 MRI characteristics of the diffuse gliomas in the 6 new enchondromatosis patients and double staining with anti-IDH1R132H and anti-ATRX
antibodies. Top: MRI findings of patient 1 to patient 6 at diagnosis (axial T2/fluid-attenuated inversion recovery (FLAIR) sequences) demonstrating
multicentric tumors in patients 1, 2, 3 and 4. Bottom: histological characteristics of the recurrent tumor of patient 3. a Hematoxylin eosin staining
demonstrating an anaplastic glioma. b IDH1 R132H expression (brown signal). c Diffuse loss of ATRX expression in tumor cells and maintained
expression (brown signal) in endothelial cells. d-g) Double staining demonstrating rare cells with a normal oligodendrocyte (black arrowheads) or
astrocyte (black arrows) morphology expressing both IDH1 R132H (red signal) and ATRX (brown signal) (inserts showing same cells at higher
magnification) and tumor cells with abnormal morphology and expressing IDH1 R132H but not ATRX (white arrows)
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and ATRX positive cells with a normal morphology
were observed (Fig. 1). Treatment consisted of surgi-
cal resection (46 %), radiotherapy (80 %) and or
chemotherapy (42 %). The median survival after gli-
oma diagnosis was 5 years.
Independent of histology and 1p/19q co-deletion status,
gliomas in enchondromatosis patients were diagnosed at
an earlier age than sporadic IDH mutated gliomas
(25.6 years versus 44 years, p < 0.001, Fig. 2). In addition,
they were more frequently multicentric (32 % versus 1 %,
p < 0.001), more frequently involved the brainstem (21 %
versus 1 %, p < 0.001) and were not associated with a 1p/
19q co-deletion (0/6 versus 59/123, p = 0.03).
Discussion
The high rate of multicentric gliomas, the identification
of IDH mutations in all of the gliomas in which it could
be fully assessed and the identical IDH mutations found
in both the glioma and the skeletal tumor of two pa-
tients strongly suggest that, in most cases, similar to
cartilaginous tumors, the development of gliomas in
enchondromatosis patients results from somatic IDH
mosaicism. The very rare IDH1 R132H and ATRX posi-
tive cells with a normal morphology found in patient 3
may further support this hypothesis. Consistent with the
demonstration of occasional IDH mutated cells in the
normal bone, blood and bone marrow of some
enchondromatosis patients, we speculate that these
cells may correspond to normal glial cells with IDH
mutations [3, 36]. However, this observation must be
taken with caution since morphology is subjective and
ATRX expression can be heterogeneous [41].
IDH mutations are considered to be the earliest onco-
genic events in the majority of lower grade gliomas [10].
In animal models, IDH mutations have been shown to
be sufficient to induce enchondromas and chondrosar-
comas [17, 29]. To our knowledge, this demonstration
has not been previously reported for gliomas, but the oc-
currence of gliomas in enchondromatosis patients, in
whom IDH mutations are thought to occur as an early
post-zygotic event suggests that IDH mutations can initi-
ate gliomagenesis [3, 36]. In addition, the median age at
glioma diagnosis in these patients (25 years) suggests
that IDH driven gliomagenesis is a very slow process. In
contrast to enchondromas, however, IDH mutation
alone is probably not sufficient to induce gliomas. Add-
itional alterations, such as ATRX and TP53 mutations,
are necessary [10]. Consistently, Moriya et al. identified
a TP53 mutation in the glioma but not in an enchon-
droma of their patient, though both lesions shared the
same IDH2 mutation [34]. This could explain why
enchondromas appear much earlier than gliomas in
enchondromatosis patients.
It is unknown why only a small percentage of enchon-
dromatosis patients (approximately 5 %) develop gliomas
[45]. It could be related to a variable distribution and
proportion of mutated cells within the brain, to the fact
that only a small percentage of IDH mutated glial cells
acquire additional alterations, or to the type of IDH mu-
tation present. In cartilaginous tumors of enchondroma-
tosis patients the IDH1 R132C mutation is more
frequent than the IDH1 R132H mutation (70 and 15 %,
respectively) [3, 36], while the IDH1 R132H mutation is
the most frequent mutation (90 %) in sporadic IDH mu-
tated gliomas [50]. Enchondromatosis patients with an
IDH1 R132H mutation could have a higher risk of devel-
oping gliomas than patients with an IDH1 R132C muta-
tion. In our series, an IDH1 R132H mutation was
present in 5 out of the 7 enchondromatosis patients who
developed diffuse glioma.
Not surprisingly, like sporadic IDH mutated gliomas,
enchondromatosis gliomas were frequently located in the
frontal lobe and were more frequently diffuse low-grade
or anaplastic gliomas than glioblastomas. However, they
differed from sporadic IDH-mutated gliomas in several as-
pects. First, they were diagnosed at an earlier age. This dif-
ference could be explained by the fact that in sporadic
IDH-mutated gliomas, the IDH mutation is acquired later
than in enchondromatosis patients. Second, enchondro-
matosis gliomas, compared to sporadic IDH mutated gli-
omas, more frequently involved the brainstem, which may
also be related to an earlier origin of enchondromatosis
Fig. 2 Age at glioma in patients with enchondromatosis and
sporadic IDH mutated gliomas according to grade and 1p/19q
co-deletion. Y axis: age at glioma diagnosis (years). X axis: OD/MS:
enchondromatosis patients with glioma, IDH: patients with sporadic
IDH mutated gliomas without 1p/19q co-deletion, Codel: patients
with sporadic IDH mutated gliomas with 1p/19q co-deletion. Median
age at glioma diagnosis, was lower in OD/MS than in IDH patients
(25.6 vs 41 years, p < 0.001) and in IDH than in Codel patients
(41 years vs 50.8 years, p < 0.001). The difference remained significant
when taking into account only LGG (OD/MS vs IDH patients: 26.9 vs
39 years, p < 0.001; IDH vs Codel patients: 39 vs 49 years, p = 0.01)
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gliomas (i.e., during the first years of life, which is a period
associated with the development of infratentorial gliomas).
Since both H3-K27M mutations (which are present in
most cases of children brainstem gliomas) and IDH muta-
tions alter histone methylation, brainstem gliomas may
therefore require histone modification of precursor cells
at an early stage of development [9, 28, 30]. This particu-
larity could help explaining why early acquisition of IDH
mutations mimics the regional preference of H3-K27M
mutated gliomas and why gliomas in that location are rare
in adults. At last, none of the 6 enchondromatosis gliomas
that could be tested were associated with a 1p/19q co-
deletion. This observation needs confirmation in a larger
series, however, again it could be related to a different tim-
ing of oncogenesis because the 1p/19q co-deletion is vir-
tually absent in pediatric gliomas [42]. Consistently, in the
present series, as in previously reported series, pa-
tients with 1p/19q co-deleted gliomas were older at
diagnosis than those with IDH mutated non 1p/19q
co-deleted gliomas [13].
Finally, multicentric gliomas were much more frequent
in enchondromatosis than in sporadic IDH-mutated gli-
omas. Multicentric gliomas (i.e., with no apparent con-
tinuity between tumors) account for 2 to 5 % of sporadic
gliomas [1]. Their oncogenesis is debated. In some cases,
evidence has been provided that the multiple tumors ac-
tually originated from the same clone [1]. However, the
multicentric presentation of gliomas reported in patients
with inherited glioma predisposition and the high inci-
dence of systemic cancers reported in patients with mul-
ticentric gliomas also suggest that multicentric gliomas
may originate from different clones in patients who have
inherited genetic alterations predisposing them to gli-
omas [4, 27]. Our study shows that somatic mosaicism
might be another mechanism leading to the develop-
ment of multicentric gliomas. It remains to be deter-
mined whether somatic IDH mosaicism might be
responsible for the occurrence of multicentric gliomas in
patients without enchondromatosis.
Conclusions
In addition to its retrospective design and its small
sample-size, limitations of the present study include the
limited number of patients in whom molecular
characterization was possible, the absence of compre-
hensive molecular analysis and the absence of IDH mu-
tation assessment in several gliomas from the same
patient. Nevertheless, the analysis of glioma characteristics
in patients with enchondromatosis sheds new light on
IDH driven gliomagenesis. It provides evidence that the
IDH mutation can initiate gliomagenesis and that the tim-
ing of IDH mutation acquisition might influence the loca-
tion and molecular characteristics of gliomas.
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